Agios Pharmaceuticals
AGIO
160 hedge funds and large institutions have $1.95B invested in Agios Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 47 increasing their positions, 61 reducing their positions, and 32 closing their positions.
5.71% more ownership
Funds ownership: 103.31% → 109.02% (+5.7%)
2% less funds holding
Funds holding: 164 → 160 (-4)
13% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 32
23% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 61
31% less capital invested
Capital invested by funds: $2.81B → $1.95B (-$865M)
51% less call options, than puts
Call options by funds: $6.91M | Put options by funds: $14M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$56.9M |
| 2 |
JP Morgan Chase
New York
|
-$46M |
| 3 |
ClearBridge Investments
New York
|
-$42.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$15.2M |
| 5 |
BlackRock
New York
|
-$14M |
AGIO Hedge Fund Activity: Q4 2021 in Review
160 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2021, worth a combined $1.95B — down 31% from $2.81B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of AGIO and 28 opened new positions — a net loss of 4 holders — while 61 trimmed existing stakes and 47 added.
The largest buyer was State Street, adding an estimated $24.2M. The largest seller was Fidelity Investments, cutting an estimated $56.9M.
- 160 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2021, down from 164 in Q3 2021.
- Funds reported $1.95B of Agios Pharmaceuticals stock for Q4 2021, down 31% quarter-over-quarter.
- 28 funds opened new Agios Pharmaceuticals positions in Q4 2021 and 32 closed out, a net change of -4 holders.
- The largest Agios Pharmaceuticals buyer in Q4 2021 was State Street, an estimated $24.2M added.
- The largest Agios Pharmaceuticals seller in Q4 2021 was Fidelity Investments, an estimated $56.9M sold.
Based on aggregated 13F filings for Q4 2021.